FitzPatrick, W. M.Dervisis, Nikolaos G.Kitchell, B. E.2016-11-152016-11-152010-12-011476-5810http://hdl.handle.net/10919/73461Doxorubicinmay cause a rare but serious cardiotoxicity. Dexrazoxane is a cardioprotectant drug used to reduce the risk of cardiotoxicity in human patients. In this study, 25 tumour-bearing dogs were treated with concurrent doxorubicin and dexrazoxane. The total number of doses of dexrazoxane given was 54 (range 1–5 doses per dog, median 2 doses). Five dogs receivedmore than 165 mg m² cumulative doxorubicin dose before starting dexrazoxane. Haematologic, gastrointestinal and cardiovascular toxicities were considered tolerable. The combination of doxorubicin with dexrazoxane was well tolerated with minimal side-effects in this patient cohort. Future studies are required to evaluate potential cardioprotective effects of dexrazoxane given concurrently with doxorubicin.273 - 282 (10) page(s)application/pdfenIn CopyrightVeterinary ScienceschemotherapydexrazoxanedoxorubicintoxicityLEFT-VENTRICULAR DYSFUNCTIONDNA TOPOISOMERASE-IIANTHRACYCLINE ANTIBIOTICSHEART-FAILURECARDIOTOXICITYADRIAMYCINCARDIOMYOPATHYDAUNORUBICINETOPOSIDEICRF-187Article - Refereedhttps://doi.org/10.1111/j.1476-5829.2010.00225.x84